Clinical Trial Update: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the long-term safety, tolerability, and efficacy of bimekizumab in active axial spondyloarthritis, including ankylosing spondylitis and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Axial Spondyloarthritis
• Nonradiographic Axial Spondyloarthritis

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Axial Spondyloarthritis, Ankylosing Spondylitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING